Trial site
Crystal Comfort S.R.O.
Vranov nad Topľou, Presov 093 01, SlovakiaEU-13 widening countryNot linked to an institution yet
- 17running trials
- 10closed trials
The trials here
What the 27 trials at this site are about, from their registry records.
- Phase
- Phase 314 trials
- Phase 211 trials
- Phase 2/32 trials
- Status
- Recruiting14 trials
- Completed10 trials
- Not yet recruiting2 trials
- Active, not recruiting1 trial
- Lead sponsor
- Intra-Cellular Therapies, Inc.3 trials
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company3 trials
- Neurocrine Biosciences3 trials
- Janssen Research & Development, LLC2 trials
- MapLight Therapeutics2 trials
- and 12 more
Running trials
Enrolling by invitation
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
NCT07459660· Phase 2· MapLight Therapeutics· Source
Recruiting
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
NCT07284472· Phase 2/3· Exciva GmbH· Source
Enrolling by invitation
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
NCT07161700· Phase 2· Seaport Therapeutics· Source
Recruiting
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
NCT06887192· Phase 2· MapLight Therapeutics· Source
Recruiting
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273· Phase 3· Bristol-Myers Squibb· Source
Recruiting
A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease
2024-513035-25-00· Phase 2· Intra-Cellular Therapies Inc.· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
NCT07065240· Phase 2· Seaport Therapeutics· Source
Recruiting
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401· Phase 3· Neurocrine Biosciences· Source
Recruiting
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06911112· Phase 3· Neurocrine Biosciences· Source
Recruiting
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
NCT06701903· Phase 2· Intra-Cellular Therapies, Inc.· Source
Recruiting
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567· Phase 2· Intra-Cellular Therapies, Inc.· Source
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Recruiting
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
NCT06540833· Phase 2· Intra-Cellular Therapies, Inc.· Source
Recruiting
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
NCT06559306· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Recruiting
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
NCT05511363· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Contact: Dagmar Breznoscakova, Site 4403
Recruiting
A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLUTION study)
2023-507372-42-00· Phase 2· Oryzon Genomics S.A.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)
2024-513104-34-00· Phase 2· HMNC Holding GmbH· Source
Completed
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
2022-502233-25-00· Phase 3· Neurocrine Biosciences Inc.· Source
Completed
A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression.
2023-508163-74-00· Phase 3· Janssen Cilag International· Source
Completed
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
NCT05729373· Phase 2/3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source
Completed
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
NCT05550532· Phase 3· Janssen Research & Development, LLC· Source
Completed
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
NCT05110157· Phase 3· Neurocrine Biosciences· Source
Completed
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
NCT04777396· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
NCT04777409· Phase 3· Novo Nordisk A/S· Source
Completed
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.
NCT04464564· Phase 3· Otsuka Pharmaceutical Development & Commercialization Inc.· Source
Completed
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression
NCT04521478· Phase 2· Boehringer Ingelheim· Source
Report an error